MarketPulse

PROSERA study

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Gossamer Bio Stock Collapses 80% on Failed Trial, Faces Securities Litigation

Gossamer Bio faces securities litigation after Phase 3 PROSERA trial failure triggered 80% stock decline, with allegations of investor deception regarding trial design and patient recruitment risks.
GOSSstock declinesecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Gossamer Bio Stock Crashes 80% After Failed Trial; Securities Lawsuit Filed

Gossamer Bio shares plunged over 80% after Phase 3 trial failure. Securities fraud lawsuit alleges misleading statements about trial design and enrollment risks.
GOSSsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Gossamer Bio Investors Face Securities Lawsuit Deadline Over Phase 3 Study Concealment

Rosen Law Firm urges Gossamer Bio investors to join securities class action alleging concealment of adverse Phase 3 PROSERA study facts. Critical deadline approaching.
IBRXGOSSIMMPsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Class Action Lawsuit Filed Against Gossamer Bio Over Misleading PAH Trial Statements

Gossamer Bio faces class action lawsuit alleging materially false statements about Phase 3 PROSERA study for pulmonary arterial hypertension treatment.
GOSSsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Gossamer Bio Hit by Securities Class Action Over Misleading Phase 3 Trial Data

Rosen Law Firm sues Gossamer Bio ($GOSS) over alleged misstatements about Phase 3 trial design. Lead plaintiff deadline: June 1, 2026.
GOSSsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Gossamer Bio Plummets 80% as Failed Phase 3 Trial Triggers Securities Lawsuit

Gossamer Bio faces class action lawsuit after Phase 3 PROSERA trial failure causes 80% stock collapse. Allegations include investor misleading on trial design and patient recruitment.
GOSSsecurities class actionstock price drop
GlobeNewswire Inc.GlobeNewswire Inc.··Gainey Mckenna & Egleston

Gossamer Bio Faces Class Action Over Failed PAH Study, Stock Plummets 80%

Gossamer Bio ($GOSS) faces class action lawsuit over failed PROSERA PAH trial; stock crashed 80% to $0.42 per share on February 23, 2026, amid allegations of misleading investor statements.
GOSSsecurities fraudclass action lawsuit